+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Daiichi Sankyo Co Ltd (4568) - Financial and Strategic SWOT Analysis Review

Daiichi Sankyo Co Ltd (4568) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Daiichi Sankyo Co Ltd (Daiichi Sankyo) is a global healthcare company that focuses on the discovery, development, and delivery of innovative medical solutions. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.

Daiichi Sankyo Co Ltd Key Recent Developments

  • Aug 21, 2024: Daiichi Sankyo Establishes New Subsidiaries In Mexico And Colombia
  • Aug 07, 2024: Daiichi Sankyo and MSD expand collaboration on ADC development
  • Jul 10, 2024: Daiichi Sankyo Launches New Affiliate for Oncology in Greece
  • Jun 28, 2024: Arbitration Dispute between Daiichi Sankyo and Seagen Ends

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Daiichi Sankyo Co Ltd - Key Facts
  • Daiichi Sankyo Co Ltd - Key Employees
  • Daiichi Sankyo Co Ltd - Key Employee Biographies
  • Daiichi Sankyo Co Ltd - Major Products and Services
  • Daiichi Sankyo Co Ltd - History
  • Daiichi Sankyo Co Ltd - Company Statement
  • Daiichi Sankyo Co Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Daiichi Sankyo Co Ltd - Business Description
  • Product Category: Healthcare (OTC) Products
  • Overview
  • Performance
  • Product Category: Others
  • Performance
  • Product Category: Prescription Drugs
  • Overview
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Japan
  • Performance
  • Geographical Segment: North America
  • Performance
  • Geographical Segment: Other Regions
  • Performance
  • R&D Overview
  • Daiichi Sankyo Co Ltd - Corporate Strategy
  • Daiichi Sankyo Co Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Daiichi Sankyo Co Ltd - Strengths
  • Daiichi Sankyo Co Ltd - Weaknesses
  • Daiichi Sankyo Co Ltd - Opportunities
  • Daiichi Sankyo Co Ltd - Threats
  • Daiichi Sankyo Co Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Daiichi Sankyo Co Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Aug 21, 2024: Daiichi Sankyo Establishes New Subsidiaries In Mexico And Colombia
  • Aug 07, 2024: Daiichi Sankyo and MSD expand collaboration on ADC development
  • Jul 10, 2024: Daiichi Sankyo Launches New Affiliate for Oncology in Greece
  • Jun 28, 2024: Arbitration Dispute between Daiichi Sankyo and Seagen Ends
  • May 29, 2024: New Subgroup Analyses of CLEAR Outcomes Data Showed Bempedoic Acid Reduced the Risk of Major Adverse Cardiovascular Events Across Various Patient Groups
  • May 22, 2024: Daiichi Sankyo Establishes Two Research Institutes In The U.S. And EU
  • May 21, 2024: Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO
  • May 14, 2024: Daiichi Sankyo Announces Appointments Of Directors
  • Mar 12, 2024: Lung Cancer Research Foundation Announces Research Grant Awards
  • Mar 12, 2024: Daiichi Sankyo Adopts Genedata Biologics to Automate the Discovery of Novel Biological Therapeutics
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Daiichi Sankyo Co Ltd, Key Facts
  • Daiichi Sankyo Co Ltd, Key Employees
  • Daiichi Sankyo Co Ltd, Key Employee Biographies
  • Daiichi Sankyo Co Ltd, Major Products and Services
  • Daiichi Sankyo Co Ltd, History
  • Daiichi Sankyo Co Ltd, Subsidiaries
  • Daiichi Sankyo Co Ltd, Joint Venture
  • Daiichi Sankyo Co Ltd, Key Competitors
  • Daiichi Sankyo Co Ltd, Ratios based on current share price
  • Daiichi Sankyo Co Ltd, Annual Ratios
  • Daiichi Sankyo Co Ltd, Interim Ratios
  • Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Daiichi Sankyo Co Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Daiichi Sankyo Co Ltd, Performance Chart (2020 - 2024)
  • Daiichi Sankyo Co Ltd, Ratio Charts
  • Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Takeda Pharmaceutical Co Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Sumitomo Pharma Co Ltd
  • Kaken Pharmaceutical Co Ltd
  • Chugai Pharmaceutical Co Ltd
  • Shionogi & Co Ltd
  • Astellas Pharma Inc
  • Taisho Pharmaceutical Holdings Co Ltd